Verasonics receives new patents – continues to focus on innovation in ultrasound research globally
KIRKLAND, Wash.–(BUSINESS WIRE)–Verasonics, Inc., the leader in ultrasound research, today announced that since February 2021, Verasonics has been awarded six new patents supporting the company’s vision to advance research and development in the areas biomedical ultrasound, materials science, earth science, and acoustics and ultrasound physics.
This is an important milestone as the Company continues to focus on developing innovative research ultrasound technologies. Verasonics’ patent portfolio now includes 74 granted patents worldwide, covering nine unique technologies. Verasonics has targeted patent coverage in key geographies including Canada, China, Denmark, France, Germany, Italy, Japan, Korea, Macao, Netherlands, Poland, the United Kingdom and the United States. The last valid claim expires in 2036.
Jon K. Daigle, President and CEO of Verasonics, said, “Our first patent was granted ten years ago. We are delighted that our patent portfolio has expanded so much over the past 10 years. This achievement marks a significant milestone for our team and its dedication to designing and providing customers, researchers and product developers with the most innovative and flexible research ultrasound technology available on the market today.
Recently granted patents include:
PRC Patent No. ZL201811519036.5: “Method and System for Generating Arbitrary Waveforms Using a Three-State Transmit Pulser.” » Vantage™ systems use a tri-state pulse generator to provide a wide power range to support both normal imaging applications and high intensity ultrasound applications. This patent covers Verasonics design for generating arbitrary waveforms using programmable duty cycle control.
Canadian Patent No. 2728998 and US Patent No. 10914826: “High Frame Rate Quantitative Doppler Flow Imaging Using Unfocused Transmit Beams”. This patent covers Vantage high frame rate Doppler sensing with long sets and unfocused beams. This feature is used for microvascular and functional imaging, spectral Doppler over the entire imaging field of view, and imaging of derived blood velocity parameters.
Japanese patent n° 6952023: “Method and system of coded excitation imaging by estimation of the impulse response and retrospective acquisition”. This patent covers the design to generate arbitrary transmission waveforms using knowledge of the transducer impulse response. This feature enables high frame rate synthetic aperture imaging with encoded transmission waveforms from each element.
Canadian Patent No. 2728998 and US Patent No. 10914826: “Estimation and Display for Vector Doppler Imaging Using Plane Wave Transmissions”. This patent covers vector Doppler imaging (imaging of flow amplitude and direction) which allows for high frame rates and robust estimation of blood velocity. Additionally, the patent covers a new display method using particle streams that visualize the direction of flow.
The Verasonics Research Ultrasound System has been cited in more than 2800 publications via customer searches in numerous scientific journals over the past twelve years. Visit the Verasonics Scientific Reference Database to learn more: https://verasonics.com/scientific-references-database/.
About Verasonics, Inc.
Verasonics is a privately held company founded in 2001, headquartered in Kirkland, Washington, USA. Verasonics is the leader in ultrasound research and is dedicated to providing researchers and developers with the most advanced and flexible tools to develop new algorithms and products used in biomedical ultrasound, materials science, earth sciences and the physics of acoustics and ultrasound. Verasonics also licenses its technology to companies for use in their commercial products. Researchers from 36 countries in North and South America, Europe, Asia and Oceania routinely use Verasonics product solutions to advance the art and science of ultrasound through their own research efforts .
To learn more, visit the Verasonics website or follow us on LinkedIn and Twitter.